Agenus submits balstilimab biologics license application to the u.s. fda for patients with recurrent or metastatic cervical cancer

Lexington, mass., april 19, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the submission of a biologics license application (bla) to the u.s. food and drug administration (fda). the bla has been submitted for the accelerated approval of balstilimab, agenus' anti-pd-1 antibody, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, and includes data from its pivotal phase 2 single-arm clinical trial, presented at the european society for medical oncology (esmo) virtual congress 2020. these clinical data, along with preclinical data, suggest that balstilimab demonstrates differentiated features from other anti-pd-1 antibodies.
AGEN Ratings Summary
AGEN Quant Ranking